BR112017020591B8 - Uso de n-{(r)-1-[8-cloro-2-(1-oxipiridin-3-il)quinolin-3-il]-2,2,2-trifluoroetil}pirido[3,2-d]pirimidin-4-ilamina - Google Patents

Uso de n-{(r)-1-[8-cloro-2-(1-oxipiridin-3-il)quinolin-3-il]-2,2,2-trifluoroetil}pirido[3,2-d]pirimidin-4-ilamina

Info

Publication number
BR112017020591B8
BR112017020591B8 BR112017020591A BR112017020591A BR112017020591B8 BR 112017020591 B8 BR112017020591 B8 BR 112017020591B8 BR 112017020591 A BR112017020591 A BR 112017020591A BR 112017020591 A BR112017020591 A BR 112017020591A BR 112017020591 B8 BR112017020591 B8 BR 112017020591B8
Authority
BR
Brazil
Prior art keywords
trifluoroethyl
ylamine
quinolin
pyrimidin
chloro
Prior art date
Application number
BR112017020591A
Other languages
English (en)
Other versions
BR112017020591A2 (pt
BR112017020591B1 (pt
Inventor
Anthony Allen Rodger
Barone Francesca
Anthony Fahy William
Nayar Saba
Original Assignee
Ucb Biopharma Sprl
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl, UCB Biopharma SRL filed Critical Ucb Biopharma Sprl
Publication of BR112017020591A2 publication Critical patent/BR112017020591A2/pt
Publication of BR112017020591B1 publication Critical patent/BR112017020591B1/pt
Publication of BR112017020591B8 publication Critical patent/BR112017020591B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

ANÁLOGO DE TRIFLUOROETILA ESPECÍFICO PARA USO NO TRATAMENTO DE SÍNDROME DE SJÖGREN. N-{(R)-1-[8-Cloro-2-(1-oxipiridin-3-il)-quinolin-3-il]-2,2,2-trifluoroetil}-pirido[3,2-d]pirimidin-4-ilamina é eficaz no tratamento e/ou na prevenção da síndrome de Sjögren.
BR112017020591A 2015-04-21 2016-04-20 Uso de n-{(r)-1-[8-cloro-2-(1-oxipiridin-3-il)quinolin-3-il]-2,2,2-trifluoroetil}pirido[3,2-d]pirimidin-4-ilamina BR112017020591B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1506786.1A GB201506786D0 (en) 2015-04-21 2015-04-21 Therapeutic use
GB1506786.1 2015-04-21
PCT/EP2016/058810 WO2016170014A1 (en) 2015-04-21 2016-04-20 A specific trifluoroethyl quinoline analogue for use in the treatment of sjögren's syndrome

Publications (3)

Publication Number Publication Date
BR112017020591A2 BR112017020591A2 (pt) 2018-07-03
BR112017020591B1 BR112017020591B1 (pt) 2023-02-07
BR112017020591B8 true BR112017020591B8 (pt) 2023-05-16

Family

ID=53298950

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017020591A BR112017020591B8 (pt) 2015-04-21 2016-04-20 Uso de n-{(r)-1-[8-cloro-2-(1-oxipiridin-3-il)quinolin-3-il]-2,2,2-trifluoroetil}pirido[3,2-d]pirimidin-4-ilamina

Country Status (27)

Country Link
US (1) US10493074B2 (pt)
EP (1) EP3285772B1 (pt)
JP (1) JP6721606B2 (pt)
KR (1) KR102627370B1 (pt)
CN (1) CN107530344B (pt)
AR (1) AR105552A1 (pt)
AU (1) AU2016251236B2 (pt)
BR (1) BR112017020591B8 (pt)
CA (1) CA2981631C (pt)
CL (1) CL2017002669A1 (pt)
CO (1) CO2017010573A2 (pt)
CY (1) CY1122572T1 (pt)
DK (1) DK3285772T3 (pt)
EA (1) EA032432B1 (pt)
ES (1) ES2763335T3 (pt)
GB (1) GB201506786D0 (pt)
HR (1) HRP20192273T1 (pt)
HU (1) HUE047162T2 (pt)
IL (1) IL254766B (pt)
LT (1) LT3285772T (pt)
MX (1) MX2017013148A (pt)
MY (1) MY192972A (pt)
PL (1) PL3285772T3 (pt)
PT (1) PT3285772T (pt)
SG (1) SG11201707789YA (pt)
SI (1) SI3285772T1 (pt)
WO (1) WO2016170014A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201708856D0 (en) 2017-06-02 2017-07-19 Ucb Biopharma Sprl Seletalisib crystalline forms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2605792T3 (es) * 2004-05-13 2017-03-16 Icos Corporation Quinazolinona usada como inhibidor de la fosfatidilinositol 3-quinasa delta humana
UA98955C2 (ru) * 2007-03-23 2012-07-10 Амген Инк. Гетероциклические соединения и их применение
AP2012006294A0 (en) * 2009-11-05 2012-06-30 Rhizen Pharmaceuticals Sa Novel kinase modulators.
UA112517C2 (uk) * 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
AR082799A1 (es) * 2010-09-08 2013-01-09 Ucb Pharma Sa Derivados de quinolina y quinoxalina como inhibidores de quinasa
NZ714710A (en) * 2013-06-14 2016-11-25 Gilead Sciences Inc Phosphatidylinositol 3-kinase inhibitors

Also Published As

Publication number Publication date
CY1122572T1 (el) 2021-01-27
JP6721606B2 (ja) 2020-07-15
BR112017020591A2 (pt) 2018-07-03
AR105552A1 (es) 2017-10-18
HUE047162T2 (hu) 2020-04-28
EA032432B1 (ru) 2019-05-31
EP3285772A1 (en) 2018-02-28
IL254766A0 (en) 2017-12-31
CN107530344B (zh) 2020-03-17
PL3285772T3 (pl) 2020-05-18
CO2017010573A2 (es) 2018-03-09
CL2017002669A1 (es) 2018-05-11
CA2981631A1 (en) 2016-10-27
LT3285772T (lt) 2020-01-10
KR20170140245A (ko) 2017-12-20
US20180092921A1 (en) 2018-04-05
WO2016170014A1 (en) 2016-10-27
DK3285772T3 (da) 2020-01-13
BR112017020591B1 (pt) 2023-02-07
AU2016251236B2 (en) 2018-06-14
CA2981631C (en) 2023-02-21
EP3285772B1 (en) 2019-10-02
HRP20192273T1 (hr) 2020-03-06
EA201792318A1 (ru) 2018-05-31
CN107530344A (zh) 2018-01-02
SG11201707789YA (en) 2017-11-29
ES2763335T3 (es) 2020-05-28
IL254766B (en) 2020-05-31
KR102627370B1 (ko) 2024-01-18
GB201506786D0 (en) 2015-06-03
MY192972A (en) 2022-09-20
AU2016251236A1 (en) 2017-11-09
SI3285772T1 (sl) 2020-02-28
JP2018513862A (ja) 2018-05-31
MX2017013148A (es) 2018-02-21
US10493074B2 (en) 2019-12-03
PT3285772T (pt) 2020-01-14

Similar Documents

Publication Publication Date Title
PH12019502318A1 (en) Trycyclic heterocycles as bet protein inhibitors
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
GB2548873B (en) Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
BR112018072450A2 (pt) análogo de trifluoroetil quinolina específico para uso no tratamento de apds
CL2015003686A1 (es) Derivados de pirrolo[3,2-d]pirimidina para el tratamiento de infecciones víricas y otras enfermedades
BR112015026006A2 (pt) métodos para o tratamento de câncer com o uso de terapia de combinação com inibidor de cinase tor
EA201692134A1 (ru) 1h-пирроло[2,3-c]пиридин-7(6h)-оны и пиразоло[3,4-c]пиридин-7(6h)-оны в качестве ингибиторов белков bet
CL2015000784A1 (es) Compuestos derivados de acilaminopirimidina, inductores de interferon; composicion farmaceutica que los comprende; su uso en el tratamiento de infecciones viricas, trastornos inmunitarios, cancer y otras enfermedades.
WO2015173633A3 (en) Hdl therapy markers
WO2015031808A3 (en) Diagnostic methods and compositions for treatment of glioblastoma
CL2013002003A1 (es) Compuestos derivados de 1, 2, 4-triazolo [4,3-a] quinoxalina, inhibidores de pde2 y/o 10; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para en el trastamiento de enfermedades del snc
TW201613935A (en) Tricyclic heterocycles as BET protein inhibitors
HK1246669A1 (zh) 人血清白蛋白低分子量組分在疾病治療中的應用
CL2016002422A1 (es) Cromeno y 1, 1a,2,7b-tetrahidrociclopropa[c]cromeno piridopirazinadionas como moduladores de gamma-secretasas.
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
BR112017020591B8 (pt) Uso de n-{(r)-1-[8-cloro-2-(1-oxipiridin-3-il)quinolin-3-il]-2,2,2-trifluoroetil}pirido[3,2-d]pirimidin-4-ilamina
WO2014117010A3 (en) Composition for ophthalmic administration
IT201700109607A1 (it) Composizione per l'uso nella prevenzione e/o nel trattamento del glaucoma.
EP3380092A4 (en) COMPOSITION OF OLIVETOL AND METHOD FOR REDUCING OR INHIBITING THE EFFECT OF TETRAHYDROCANNABINOL IN THE HUMAN BODY
ITUA20162781A1 (it) Kit di medicamenti per l’uso nel trattamento di lesioni dei tessuti tegumentari.
CL2018001871A1 (es) Uso de inhibidores de la actividad o función de pi3k para el tratamiento del síndrome de sjögren primario
GB201901871D0 (en) Cannabidiol and/or derivatives thereof for use in the treatment of mitochondrial diseases
CL2015003683A1 (es) Letermovir amorfo formulación oral farmacéutica que lo comprende uso de la formulación en la preparación de un medicamento útil en el tratamiento yo profilaxis de enfermedades asociadas con el grupo de herpesviridae, preferiblemente asociadas con citomegalovirus cmv proceso de preparación de letermovir amorfo.
UA115417U (xx) Спосіб профілактики та лікування гіпоксичних змін при карбоперитонеумі
TH1501004454B (th) สต๊อปเปอร์กำหนดตำแหน่งส่วนลำตัวยานพาหนะที่สูงขึ้น-ลดต่ำลงในส่วนช่วงล่างของยานยนต์

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/04/2016, OBSERVADAS AS CONDICOES LEGAIS

B25D Requested change of name of applicant approved

Owner name: UCB BIOPHARMA SRL (BE)